Adma Biologics (ADMA) Inventory Average (2012 - 2025)

Adma Biologics' Inventory Average history runs 11 years deep, the most recent figure standing at $201.6 million for Q4 2025.

• Quarterly Inventory Average rose 17.86% year-over-year to $201.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $201.6 million (up 17.86% YoY) and the FY2025 annual result came in at $188.4 million, up 9.78% from the prior year.
• Inventory Average was $201.6 million for Q4 2025 at Adma Biologics, up from $194.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $201.6 million in Q4 2025 and bottomed at $87.8 million in Q1 2021.
• A 5-year average of $155.5 million and a median of $163.4 million in 2022 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2021 — Inventory Average jumped 66.75% — and 2025, when it declined 2.34%.
• Adma Biologics' Inventory Average stood at $119.4 million in 2021, then soared by 36.57% to $163.1 million in 2022, then gained by 3.01% to $168.0 million in 2023, then rose by 1.79% to $171.0 million in 2024, then grew by 17.86% to $201.6 million in 2025.
• Business Quant data shows ADMA's Inventory Average at $201.6 million in Q4 2025, $194.1 million in Q3 2025, and $181.8 million in Q2 2025.